Soluble Neprilysin does not Correlate with Outcome in Heart Failure with Preserved Ejection Fraction
Open Access
- 1 January 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 18 (1) , 89-93
Abstract
Aims Circulating soluble neprilysin, an endopeptidase that catalyses the degradation of various endogenous vasodilators, predicts outcome in patients with heart failure and reduced ejection fraction (HFrEF). In the present study, we measured for the first time circulating soluble neprilysin in a prospective cohort of patients with heart failure with preserved ejection fraction (HFpEF) and correlated the serum levels to outcome, functional markers, established risk factors for HFpEF, myocardial fibrosis assessed by cardiac magnetic resonance (CMR) imaging, as well as histological data obtained by myocardial biopsy and various invasive haemodynamic measurements. Methods and results We prospectively included 144 consecutive patients with HFpEF in our observational, non-interventional registry. Echocardiography, CMR imaging, and invasive haemodynamic assessments including myocardial biopsy were performed at baseline. We did not observe a significant association between soluble neprilysin levels and hospitalization for heart failure and/or death in the Cox regression analysis (P = 0.56). Furthermore, there were no significant differences between tertiles of neprilysin in outcome, functional markers, established risk factors for HFpEF, CMR measurements including post-contrast T1 time, extracellular matrix obtained by myocardial biopsy, and invasive haemodynamic measurements. NT-proBNP demonstrated a weak correlation with levels of soluble neprilysin (r = − 0.26, P = 0.002). Conclusion Our results describe for the first time circulating levels of soluble neprilysin in patients with HFpEF. In contrast to HFrEF, we could not confirm an association between neprilysin levels and cardiovascular mortality or hospitalization for heart failure.Keywords
This publication has 13 references indexed in Scilit:
- Prognostic Value and Kinetics of Soluble Neprilysin in Acute Heart FailureJACC: Heart Failure, 2015
- Renal Effects of the Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Patients with Heart Failure and Preserved Ejection FractionEuropean Journal of Heart Failure, 2015
- Soluble Neprilysin Is Predictive of Cardiovascular Death and Heart Failure Hospitalization in Heart Failure PatientsJACC, 2015
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureNew England Journal of Medicine, 2014
- Cardiac Magnetic Resonance Postcontrast T1 Time Is Associated With Outcome in Patients With Heart Failure and Preserved Ejection FractionCirculation: Cardiovascular Imaging, 2013
- A Novel Paradigm for Heart Failure With Preserved Ejection FractionJACC, 2013
- The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trialThe Lancet, 2012
- ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012European Journal of Heart Failure, 2012
- Neprilysin Null Mice Develop Exaggerated Pulmonary Vascular Remodeling in Response to Chronic HypoxiaThe American Journal of Pathology, 2009
- How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of CardiologyEuropean Heart Journal, 2007